Can Cellares bring down the cost of some of the most expensive new therapies on the market?
I recently had the pleasure of sitting down with Fabian Gerlinghaus, CEO of Cellares. They are working on closed-system full automation to manufacture cell therapies.
This was at JPM Week 2025 in San Francisco.
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
With a median progression-free survival nearing four years in ROS1 lung cancer, Nuvation Bio’s breakthrough therapy signals a turning point for precision oncology - validating Dr. David Hung’s patient-first vision.
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
